Juntendo Medical Journal, 2026 Original Articles Juntendo Medical Journal 2026 Longitudinal Assessment of Metabolic Syndrome and Direct-Acting Antiviral (DAA) Treatment Adherence in Hepatitis C Patients Christa MATHEW1), Saud GUL2), Manahil MONIS3), Sadia Binte TARIQ4), Arooba FNU5), Aimen JAMES6), Abeeha MAHMOOD7), Zill-e-Rukh Fatima AMER7), Loloa Raed Mohammad ALBSOUL8), Mohammed Hakim Shah Chun MOHAMMED9), Reuel Abraham KURUDAMANNIL9), Bilal Mohammad SHAFIQ10), Reem Ashraf Fathy ZALAT9) 1)Department of Medicine, Royal Devon University Healthcare NHS Foundation Trust, Barnstaple, United Kingdom 2)Department of Medicine, Royal Derby Hospital, Derby, United Kingdom 3)Department of Medicine, Foundation University Medical College, Islamabad, Pakistan 4)Department of Medicine, Fatima Jinnah Medical University, Lahore, Pakistan 5)Department of Medicine, People’s University of Medical & Health Sciences for Women (PUMHSW), Nawabshah (SBA), Pakistan 6)Department of Cardiology, Queen Elizabeth Hospital, King’s Lynn, United Kingdom 7)Department of Medicine, CMH Lahore Medical College, Lahore, Pakistan 8)Department of Medicine, University of Badji Mokhtar Annaba, Annaba, Jordan 9)Department of Medicine, NMC Specialty Hospital, Abu Dhabi, United Arab Emirates 10)Department of Medicine, Ternopil National Medical University, Ternopil, Ukraine Objectives: Chronic hepatitis C is commonly associated with metabolic abnormalities that can influence adherence to directacting antiviral (DAA) therapy. This paper discussed the relationship between metabolic syndrome risk and compliance with DAA for 6 months. Materials and Methods: A longitudinal observational study was conducted among 402 patients with chronic hepatitis C taking DAA. Metabolic risk was measured using the Metabolic Screening Questionnaire (MSQ), and treatment adherence was measured at baseline, 3 months and 6 months using the Morisky Medication Adherence Scale (MMAS-8). Descriptive statistics, Spearman correlations, Mann-Whitney U test, Kruskal-Wallis tests and repeated-measures ANOVA were used as statistical tests. Results: Adherence at baseline (ρ = 0.28, p < 0.001), after 3 months (ρ = 0.22, p < 0.001), and after 6 months (ρ = 0.26, p < 0.001) was significantly associated with metabolic risk in a negative direction. Women adhered more than men (U = 16,950, p = 0.002), and men were more at risk of metabolism (U = 17,250, p = 0.008). MSQ (χ2 = 12.84, p = 0.012) and MMAS-8 (χ2 = 10.92, p = 0.028) differed in terms of age. Compliance at baseline (12.74) was compared with that at 6 months (13.62; F = 21.67, p < 0.001), and with metabolic risk being a significant mediator (F = 7.18, p < 0.001). Conclusion: Reduced treatment adherence to DAA therapy is closely associated with increased metabolic risk. Implementing metabolic risk management into standard care can enhance adherence and treatment outcomes among patients with hepatitis C. Key words: hepatitis C, direct-acting antivirals (DAAs), metabolic syndrome, medication adherence, longitudinal study Corresponding author: Aimen James Department of Cardiology, Queen Elizabeth Hospital Gayton Rd, King's Lynn PE30 4ET, United Kingdom TEL: +44-203-889-4176 〔Received E-mail: Aimenjames72@gmail.com Dec. 2, 2025〕 〔Accepted Jan. 12, 2026〕 J-STAGE Advance published date: Mar. 13, 2026 Copyright © 2026 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited. doi: 10.14789/ejmj.JMJ25-0063-OA 1 Mathew C, et al: Metabolic syndrome & DAA adherence in hepatitis C Introduction Hepatitis C virus (HCV) is a blood-borne, hepa­ totropic RNA virus that leads to progressive liver disease; the most common genotypes are 1, 3, and 4, and direct-acting antivirals (DAAs) are highly effective for achieving viral clearance1, 2). HCV is a significant cause of chronic liver disease, cirrhosis, hepatocellular carcinoma, and extrahepatic compli­ cations, affecting approximately 3% of the global population. Disease progression depends on host, viral, and environmental factors3, 4). HCV infection has been linked to extrahepatic syst­ emic complications, such as cardiovascular, kidney, and metabolic complications. Genetic variants, such as PNPLA3 and TM6SF2, have been shown to infl­ uence the risk of metabolic complications and the severity of chronic kidney disease (CKD) in patients with HCV5, 6). Metabolic imbalances such as insulin resistance, glucose and lipid regulation, and athero­ sclerosis are also associated with chronic HCV infec­ tion and not only influence chronic progression of liver disease, but also add to systemic extrahepatic manifestations7). DAAs have demonstrated the ability to clear HCV, improve both hepatic and extrahepatic outcomes, and reduce cardiovascular and metabolic risks. Neve­ rtheless, more severe liver disease can increase the risk of hepatocellular carcinoma8). Although IFNfree DAAs have dramatically improved outcomes, treatment adherence remains suboptimal (~52%), with lack of follow-up and limited disease aware­ ness representing significant barriers, particularly among patients with hepatocellular carcinoma9). The interaction between metabolic syndrome and DAA compliance to achieve optimal HCV outcomes needs to be understood. Although metabolic compli­ cations and treatment adherence have been studied separately by other researchers, few longitudinal studies combine both measures. This type of rese­ arch is critical for identifying patients at increased risk of worse outcomes and for informing specific interventions aimed at improving not only patients' metabolic status but also compliance with antiviral therapy. This study aims to longitudinally assess the occu­ rrence and progression of metabolic syndrome in patients receiving DAA therapy for HCV, while concurrently evaluating patterns of treatment adher­ 2 ence. By integrating these analyses, the study seeks to inform clinical decision-making and improve overall care for patients with HCV. Objectives The purpose of the proposed research is to longi­ tudinally evaluate the prevalence and progression of metabolic syndrome in patients with chronic hepatitis C receiving DAA treatment, as well as to assess longitudinal treatment adherence throughout. The research seeks to establish relationships between metabolic risk factors and adherence patterns, and to offer insights into factors that might determine the effectiveness of DAA treatment in people with HCV, and to guide strategies to maximise metabolic health and the overall efficacy of DAA treatment. Materials and Methods Study design and setting This was a longitudinal observational study cond­ ucted between March 2025 and September 2025. The research aimed to evaluate metabolic syndrome and compliance with treatment in patients with chronic hepatitis C undergoing DAA treatment thro­ ughout the treatment. Study population Individuals were eligible to participate in the study if they met the following criteria: patients aged 18 years or older with a known chronic hepatitis C infection who were receiving DAA therapy. The exclusion criteria were: co-infection with hepatitis B or HIV, decompensated liver disease, pregnancy, or a condition that might be a limiting factor to study follow-up or proper evaluation of metabolic parameters. Sample size and sampling technique This study used convenience sampling to recruit 402 patients who were available and willing to parti­ cipate throughout the study period. The sample size was estimated from an infinite target population, as no specific count of adults with hepatitis C in the study area was available. A 95% confidence level and a 5% margin of error were used, and a conser­ vative estimate of 50% prevalence was employed to ensure the maximum sample size and account for population variation10). Juntendo Medical Journal, 2026 Data collection tools The data were collected at the baseline and the follow-up with the use of structured questionnaires, including: Demographic and clinical data: Baseline data incl­ uded age, gender, body mass index (BMI), lifestyle (diet, exercise, smoking), and comorbidities to char­ acterise the study population. Metabolic screening questionnaire: Metabolic health was assessed using a structured questionnaire that measured parameters needed to identify metabolic syndrome according to the International Diabetes Federation (IDF) 2006 criteria. The IDF consensus definition, developed by Alberti K.G.M., Zimmet P., Shaw J., et al., defines metabolic syndrome as central obesity and two of the following: elevated triglyce­ rides, decreased HDL cholesterol, elevated blood pressure, or elevated fasting plasma glucose11). The study employed this questionnaire to filter out poss­ ible metabolic risk factors and identify the exis­ tence of metabolic syndrome in patients with hepa­ titis C. It should be noted that while the MSQ was used to identify potential metabolic risk factors, biochemical confirmation (such as fasting glucose, lipid profile, or blood pressure measurements) was beyond the scope of this study. Morisky medication adherence scale (MMAS-8): The 8-item Morisky Medication Adherence Scale (MMAS-8), which was developed by Donald Morisky in 2008, was used to assess adherence to DAA therapy. The MMAS-8 is a well-established selfreport questionnaire that is used to evaluate medi­ cation-taking behaviour. It consists of 8 questions: 7 yes/no and one rated on a 5-point Likert scale. The overall scores range from 0 to 8, with higher scores indicating improved adherence. The compli­ ance falls under high (score 8), medium (score 6 to < 8), and low (score < 6)12). To identify patterns of DAA therapy adherence over time, longitudinal adherence was measured using the MMAS-8 at baseline, 3 months, and 6 months. For clarity, the mean MMAS-8 scores reported in the Results section reflect the average adherence level of all participants at each time point. Ethical considerations The study protocol was approved by the ethical review committee of Queen Elizabeth Hospital (IRB: QEH-RD-ETHICS-25-1673). The participants in the study were informed about the study's purpose, methods, and potential risks and benefits. Oral informed consent was taken before data collection. The patient's confidentiality was maintained with great care throughout the study. Participation was voluntary, and patients could drop out at any time without affecting their treatment. Data analysis SPSS version 26 was used to analyse the data. The demographic and clinical characteristics, i.e., metabolic risk and medication adherence, were summarised using descriptive statistics (frequencies, percentages, and mean ranks where appropriate). The relationship between baseline, 3-month, and 6month metabolic risk (MSQ) and medication adhe­ rence (MMAS-8) was examined using Spearman's rank-order correlation. Metabolic risk and compli­ ance were compared across gender and age groups using the Mann-Whitney U test and the KruskalWallis test, respectively. A repeated-measures ANOVA was used to assess longitudinal variation in medication adherence over time and to examine the interaction between medication adherence and metabolic risk. Any p-value below 0.05 was deemed statistically significant. Demographic and clinical characteristics of the study participants The demographic and clinical profile of 402 parti­ cipants is characterised in Table 1. The majority were aged 50-59 years (48.8%), with a slightly larger proportion of women (51.5%). Marital status varied, with the most significant subgroups being divorced or separated (29.6%), married (25.9%), and single (24.4%). Educational levels varied, but almost half had no formal education or only a primary educa­ tion. Employment was evenly distributed: 31.1% of respondents were employed, with the rest being students, unemployed, or retirees. The BMI catego­ ries showed that the majority consisted of under­ weight (31.6%) participants, followed by 24.1% overweight and obese (20.6%). The prevalence of smoking was high, with 44.5% being current smokers. A large percentage of respondents had chronic conditions, such as diabetes (28.4%) and high blood pressure (27.9%). Over 50% had a history of 4 or more years of HCV diagnosis, and a considerable percentage (44.0%) of those infected had under­ 3 Mathew C, et al: Metabolic syndrome & DAA adherence in hepatitis C Table 1 Variable Demographic characteristics of participants (N = 402) f % Age Variable f % Body mass index (BMI) 18-29 years 11 2.7 Underweight (< 18.5) 127 31.6 30-39 years 56 13.9 Normal weight (18.5-24.9) 95 23.6 40-49 years 103 25.6 Overweight (25-29.9) 97 24.1 50-59 years 196 48.8 Obese (≥ 30) 83 20.6 60 years and above 36 9.0 Smoking status Never smoked 93 23.1 Gender Male 195 48.5 Former smoker 130 32.3 Female 207 51.5 Current smoker 179 44.5 History of chronic conditions 175 58.3 Marital status Single 98 24.4 Hypertension 112 27.9 Married 104 25.9 Diabetes mellitus 114 28.4 Divorced/Separated 119 29.6 Hyperlipidemia 73 18.2 Widowed 81 20.1 Cardiovascular disease 59 14.7 None of the above 44 10.9 Educational level No formal education 89 22.1 Duration since HCV diagnosis Primary school 90 22.4 < 1 year 107 26.6 Secondary school/High school 95 23.6 1-3 years 73 18.2 Graduate (Bachelor's) 85 21.1 4-6 years 128 31.8 Postgraduate (Master's or above) 43 10.7 > 6 years 94 23.4 Employment status Previous HCV treatment history Student 86 21.4 Treatment-naïve 160 39.8 Employed 125 31.1 Previously treated with interferon-based therapy 177 44.0 Unemployed 90 22.4 Previously treated with DAAs 65 16.2 Retired 101 25.1 Note. N = number of participants; f = frequency, % = percentage gone treatment with interferon-based regimens, with 39.8% being treatment-naive. there is no significant difference in adherence beha­ viours across follow-up times. Correlation between metabolic risk and medication adherence across follow-up periods Table 2 indicates a significant correlation between metabolic risk and medication adherence at all time points. Increased scores of metabolic risk were consistently correlated with reduced baseline, 3 months, and 6 months medication adherence (0.22 0.28, all p < 0.001). Baseline medication adherence scores were positively associated with adherence at 3 and 6 months, suggesting consistent adherence over time. On the same note, compliance at 3 months was highly associated with compliance at 6 months. Overall, the findings indicate that greater meta­ bolic risk is associated with poorer adherence, but Gender differences in metabolic risk and medication adherence According to Table 3, there is a significant differ­ ence between genders in terms of metabolic risk and medication adherence. The metabolic risk scores were higher in men than in women, with a signifi­ cantly higher mean rank (215.60 vs. 187.20; U = 17,250, p = 0.008). Women, in contrast, showed much higher medication adherence than men (mean rank 216.00 vs. 185.50; U = 16,950, p = 0.002). These results indicate that males in the sample were more at risk of metabolic disorders, and females were more likely to take medication. 4 Juntendo Medical Journal, 2026 Table 2 Spearman's rank-order correlations between metabolic risk and medication adherence across time points (N = 402) Metabolic screening questionnaire (MSQ) Morisky medication adherence scale (Baseline) Morisky medication adherence scale (3 months) Morisky medication adherence scale (6 months) Metabolic screening questionnaire (MSQ) - ρ = -0.28, t = -5.88, p = < 0.001*** ρ = -0.22, t = -4.52, p = < 0.001*** ρ = -0.26, t = -5.43, p = < 0.001*** Morisky medication adherence scale (Baseline) - - ρ = 0.34, t = 7.27, p = < 0.001*** ρ = 0.41, t = 9.01, p = < 0.001*** Morisky medication adherence scale (3 months) - - - ρ = 0.38, t = 8.23, p = < 0.001*** Morisky medication adherence scale (6 months) - - - - Variable Note. ***= p < 0.001 considered significant; Positive correlations indicate direct relationships, and negative correlations indicate inverse relationships; N = 402. Table 3 Gender differences in metabolic risk and medication adherence based on Mann-Whitney U tests (N = 402) Variable Metabolic screening questionnaire (MSQ) Morisky medication adherence scale (MMAS-8) Gender N Mean rank Sum of ranks U Z p Male 195 215.60 42,042.00 - - - Female 207 187.20 38,750.40 17,250 -2.65 0.008** Male 195 185.50 36,172.50 - - - Female 207 216.00 44,712.00 16,950 -3.05 0.002** Note. N = 402 (Males = 195, 48.5%; Females = 207, 51.5%); Mann-Whitney U test was used for all comparisons; p values marked with ** indicate statistical significance at p < 0.01 Age-related differences in metabolic risk and medication adherence Table 4 shows a significant difference in metabolic risk and medication adherence between the age groups. The metabolic risk (MSQ scores) showed considerable variability, with the highest mean rank observed in the 30-39 and 40-49 age groups, and the lowest rank observed in the youngest (18-29) Table 4 and the oldest (60+) participants (χ2 = 12.84, p = 0.012). Age also significantly differed in medication adherence (MMAS-8 scores), with the youngest and the oldest (ages 40 and above, respectively) having the lowest levels of adherence (χ2(4) = 10.92, p = 0.028). Overall, the results show that metabolic risk levels and adherence change with age, peaking in middle adulthood and declining thereafter.  ifferences in metabolic risk and medication adherence across age groups based on KruskalD Wallis tests (N = 402) Variable Metabolic screening questionnaire (MSQ) Morisky medication adherence scale (MMAS-8) Age group N Mean rank x2(df = 4) p 18-29 years 11 150.00 - - 30-39 years 56 225.00 - - 40-49 years 103 230.50 - - 50-59 years 196 215.80 - - 60 years or above 36 180.40 12.84 0.012* 18-29 years 11 160.00 - - 30-39 years 56 210.90 - - 40-49 years 103 215.30 - - 50-59 years 196 220.80 - - 60 years or above 36 175.20 10.92 0.028* Note. N = number of participants in each age category; % = percentage of the total sample; Percentages are based on total N = 402; Values are mean ranks from Kruskal-Wallis H tests; Overall test statistics are reported in the bottom row for each dependent variable: Total MSQ (χ2(4) = 12.84, 0.012*) and Total MMAS-8 (χ2(4) = 10.92, 0.028*); Significance levels: p < 0.05* 5 Mathew C, et al: Metabolic syndrome & DAA adherence in hepatitis C Changes in medication adherence over time and interaction with metabolic risk Table 5 shows a considerable difference in medi­ cation adherence, with MMAS-8 scores higher at baseline (M = 12.74), 3 months (M = 13.29), and 6 months (M = 13.62). Repeated-measures ANOVA revealed a significant main effect of time (F = 21.67, p < 0.001, partial η 2 = 0.097), indicating that adher­ ence increased significantly over time. The time × metabolic risk interaction was also significant (F = 7.18, p < 0.001, partial η 2 = 0.034), indicating that adherence varied across levels of metabolic risk. The total compliance levels increased gradually over time, and metabolic risk influenced these vari­ ations. study, with males having a higher metabolic risk than females. This is unlike in some populationbased studies, which revealed that the prevalence rate of metabolic syndrome is higher in women. Still, it reminds us that gender-specific metabolic patterns might vary across populations14). MMAS -8 scores indicated higher medication adherence among females compared to males. This finding runs counter to a wide range of claims-based rese­ arch reporting lower adherence among women, and it provides evidence that adherence patterns are not universal in clinical and population-based settings15). We observed greater metabolic risk in middleaged participants (30-49 years), consistent with a previous study reporting the highest incidence of metabolic syndrome among men aged 40-49 years, suggesting that midlife is the critical phase for accu­ mulating metabolic risk16). Interestingly, younger and older adults also had lower adherence levels, although middle-aged participants were the most adherent. This is, in part, in line with prior research that has found higher non-adherence among younger adults than among older adults, with the implica­ tion that adherence increases with age as individ­ uals age into middle age17). Similar to our finding of increased adherence at 6 months (MMAS-8: 12.74, 13.62), previous longitu­ dinal studies have reported improvement in medi­ cation adherence at that time as well, highlighting the importance of continued patient support and beliefs in adherence18). In addition, it has been previ­ ously determined that worse compliance is associ­ Discussion This longitudinal study examined the relation­ ship between metabolic syndrome risk and treatment adherence in chronic hepatitis C patients receiving DAA therapy. The findings indicate that metabolic risk is closely correlated with medication adher­ ence, with higher metabolic risk consistently asso­ ciated with lower adherence at baseline, 3 months, and 6 months. These findings are consistent with previous studies among patients with metabolic syndrome, where nearly 43% of the sample reported low medication adherence, particularly among pati­ ents with high disease burden and complex treat­ ment schedules13). These results indicate that an integrated approach to care, including metabolic well-being and antiviral therapy, is necessary. A gender difference was also observed in our Table 5  epeated measures ANOVA for changes in medication adherence (MMAS-8) over time and interaction R with metabolic risk (MSQ) Time Point Mean SD N - - - Morisky medication adherence scale (baseline) 12.74 1.45 402 - - - Morisky medication adherence scale (3 months) 13.29 1.52 402 - - - Morisky medication adherence scale (6 months) 13.62 1.53 402 - - - Source Type III SS df Mean square F p Partial η2 Time 18.45 2 9.225 21.67 <0.001*** 0.097 Time × total metabolic screening questionnaire (MSQ) 6.12 2 3.060 7.18 <0.001*** 0.034 Error(time) 341.75 800 0.427 — — — Note. ***p < 0.001. Partial η represents effect size. 2 6 Juntendo Medical Journal, 2026 ated with a higher level of metabolic risk factors, such as central obesity. Our study expands on this information by demonstrating that metabolic risk predicts not only reduced adherence but also influ­ ences adherence dynamics19). The overall findings of these studies indicate that multifaceted management methods that integrate assessment of metabolic risks, patient education, and adherence support can improve clinical outcomes for patients receiving antiviral therapy. Interven­ tions targeting metabolic risk, such as lifestyle modification, dietary counselling, and structured physical activity programs, may indirectly enhance DAA adherence by improving patients’ overall health, motivation, and engagement with treatment. More­ over, tailored patient education and regular followup can empower individuals to manage metabolic risk factors better and improve adherence to anti­ viral therapy, ultimately leading to better longterm outcomes. Limitations and recommendations This research has several limitations. Self-reported questionnaires (MMAS-8 and MSQ) and conve­ nience sampling could limit generalisability and introduce bias. The assessment of metabolic risk was not performed, and the verification of biochem­ ical factors and clinical outcomes, such as SVR or changes in liver function, was not analysed. Possible confounders (depression or socioeconomic factors) were not accounted for, and the follow-up period was only 6 months, which may not reflect longterm outcomes. Future research should include biochemical markers of metabolic syndrome, larger probabilitybased samples, and clinical outcome measures. Psyc­ hosocial predictors and intervention strategies, including counselling or digital reminders, must also be sought to enhance adherence. Follow-up periods and gender- or age-specific strategy can be extended to understand adherence patterns better. Conclusion The research indicates that there is a strong correlation between treatment adherence and meta­ bolic syndrome risk amongst chronic hepatitis C patients receiving DAA therapy, with better adher­ ence rates related to increased metabolic risk, and the reverse also being true. Gender and age were significant variables affecting both metabolic risk and compliance patterns. The findings suggest that there should be integrated clinical strategies for metabolic health and adherence to behaviour. Early identification of patients at high metabolic and adherence risk throughout treatment would enable medical professionals to implement targeted meas­ ures to improve antiviral therapy response and health outcomes.